MARKET

OCUP

OCUP

Ocuphire Pharma Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.130
-0.010
-0.47%
Opening 11:23 05/27 EDT
OPEN
2.140
PREV CLOSE
2.140
HIGH
2.170
LOW
2.130
VOLUME
74.50K
TURNOVER
154.10K
52 WEEK HIGH
7.00
52 WEEK LOW
1.800
MARKET CAP
41.25M
P/E (TTM)
-1.4427
1D
5D
1M
3M
1Y
5Y
Ocuphire's Nightblindness Candidate Meets Primary Endpoint In Phase 3 Study
Ocuphire Pharma Inc (NASDAQ: OCUP) has 
Benzinga · 05/19 15:12
NeuroMetrix, Zealand Pharma top healthcare gainers; China SXT, Ocuphire lead losers' pack
Gainers: NeuroMetrix (NURO) +45%. Zealand Pharma (ZEAL) +18%. SIGA Technologies (SIGA) +16%. Indaptus Therapeutics (INDP) +15%. Immix Biopharma (IMMX) +13%. Losers: China SXT Pharmaceuticals (SXTC) -20%. Ocuphire Pharma (OCUP) -9%. Enanta Pharmaceuticals (...
Seekingalpha · 05/19 14:05
Cisco Systems, UWM Holdings, Kohl's among premarket losers' pack
Vinco Ventures (BBIG) -14%. Cisco Systems CSCO -12% on Q3 earnings release. Decisionpoint Systems (DPSI) -10%. Ocuphire Pharma OCUP -10% despite main goal met for Nyxol late-stage trial for night vision disturbances. Kohl's KSS -9% on Q1
Seekingalpha · 05/19 12:19
Ocuphire says main goal met for Nyxol late-stage trial for night vision disturbances
Ocuphire Pharma (NASDAQ:OCUP), a clinical-stage biotech focused on eye diseases, announced on Thursday that its Phase 3 pivotal clinical trial for Nyxol met the FDA-agreed primary endpoint in patients with
Seekingalpha · 05/19 12:03
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/19 12:01
BRIEF-Ocuphire Announces Positive Topline Results From Phase 3 Trial Evaluating Nyxol Eye Drops
reuters.com · 05/19 11:03
Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances
Met FDA-agreed Primary Endpoint with More Nyxol Subjects Gaining 3 Lines of Low Contrast Distance Vision under Dim Light Conditions Compared to Placebo First to Demonstrate Efficacy in Phase 3 Trial for the Large Unmet Need of Treating Night Vision Disturb...
GlobeNewswire · 05/19 11:00
Ocuphire Pharma Reports Positive Topline Results From Phase 3 Trial of Nyxol to Treat Night Vision Disturbances
MT Newswires · 05/19 07:22
More
No Data
Learn about the latest financial forecast of OCUP. Analyze the recent business situations of Ocuphire Pharma Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

16.67%Strong Buy
83.33%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average OCUP stock price target is 23.83 with a high estimate of 29.00 and a low estimate of 12.00.
High29.00
Average23.83
Low12.00
Current 2.130
EPS
Actual
Estimate
-0.42-0.31-0.21-0.10
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 51
Institutional Holdings: 2.06M
% Owned: 10.64%
Shares Outstanding: 19.36M
TypeInstitutionsShares
Increased
9
115.62K
New
10
103.36K
Decreased
10
234.62K
Sold Out
7
95.42K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.07%
Pharmaceuticals & Medical Research
+0.46%
Key Executives
Non-Executive Chairman/Independent Director
Cam Gallagher
President/Chief Executive Officer/Vice Chairman/Treasurer/Director
Mina Sooch
Chief Accounting Officer/Vice President - Finance
Amy Rabourn
Vice President - Operations
Bernhard Hoffmann
Lead Director/Independent Director
Sean Ainsworth
Director
Jay Pepose
Independent Director
Susan Benton
Independent Director
James Manuso
Independent Director
Richard Rodgers
No Data
No Data
About OCUP
Ocuphire Pharma, Inc., formerly Rexahn Pharmaceuticals, Inc., is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of eye disorders. Its pipeline includes two small-molecule product candidates targeting front and back of the eye indications. Its lead product candidate, Nyxol Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol is being developed for several indications, including dim light or night vision disturbances (NVD), reversal of pharmacologically induced mydriasis (RM) and presbyopia. Its second product candidate, APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME). Its pre-clinical product candidates are APX2009 and APX2014.

Webull offers kinds of Ocuphire Pharma Inc stock information, including NASDAQ:OCUP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCUP stock methods without spending real money on the virtual paper trading platform.